Santos Castañeda Sanz-rekin lankidetzan egindako argitalpenak (11)

2024

  1. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2022

  1. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 988-992

2021

  1. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  2. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 38, Núm. 6, pp. 1201-1205

  2. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 37, Núm. 3, pp. 465-473

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

2015

  1. Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

    Medicine (United States), Vol. 94, Núm. 39, pp. e1554

  2. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 717-723

2014

  1. Tocilizumab in refractory aortitis: A study on 16 patients and literature review

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82